Myriad Genetics Inc (MYGN) stock
MYGNNasdaqIn Vitro & In Vivo Diagnostic SubstancesFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 6, 2026Score 8/3070% below fair value
$5.53−0.01 (-0.18%)
Close on Nov 18, 2026Market cap $528.94MP/E –Yield –
Myriad Genetics operating income
Operating income is the profit from the core business after operating expenses such as R&D and selling costs, before interest and taxes.
Myriad Genetics's operating income for the twelve months ending Jun 30, 2026 was -$98.60M. For fiscal 2025 it was -$387.20M. The highest annual figure on record is $274.40M in fiscal 2014.
Annual operating income
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$387.20M | – |
| FY2024 | Dec 31, 2024 | -$123.50M | – |
| FY2023 | Dec 31, 2023 | -$257.40M | – |
| FY2022 | Dec 31, 2022 | -$140.60M | – |
| FY2020 | Jun 30, 2020 | -$231.70M | -3148.7% |
| FY2019 | Jun 30, 2019 | $7.60M | -93.8% |
| FY2018 | Jun 30, 2018 | $121.90M | +177.0% |
| FY2017 | Jun 30, 2017 | $44.00M | -71.3% |
| FY2016 | Jun 30, 2016 | $153.40M | +14.8% |
| FY2015 | Jun 30, 2015 | $133.60M | -51.3% |
| FY2014 | Jun 30, 2014 | $274.40M | +20.4% |
| FY2013 | Jun 30, 2013 | $228.00M | +26.4% |
| FY2012 | Jun 30, 2012 | $180.32M | +14.3% |
| FY2011 | Jun 30, 2011 | $157.78M | +16.8% |
| FY2010 | Jun 30, 2010 | $135.08M | +6.8% |
| FY2009 | Jun 30, 2009 | $126.46M | – |
Quarterly operating income
Change is against the same quarter a year earlier.
Periods
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026CQ2 2026 | Jun 30, 2026 | -$38.90M | – |
| Q1 FY2026CQ1 2026 | Mar 31, 2026 | -$30.70M | – |
| Q4 FY2025CQ4 2025 | Dec 31, 2025 | -$5.70M | – |
| Q3 FY2025CQ3 2025 | Sep 30, 2025 | -$23.30M | – |
| Q2 FY2025CQ2 2025 | Jun 30, 2025 | -$329.20M | – |
| Q1 FY2025CQ1 2025 | Mar 31, 2025 | -$29.00M | – |
| Q4 FY2024CQ4 2024 | Dec 31, 2024 | -$39.00M | – |
| Q3 FY2024CQ3 2024 | Sep 30, 2024 | -$20.00M | – |
| Q2 FY2024CQ2 2024 | Jun 30, 2024 | -$36.50M | – |
| Q1 FY2024CQ1 2024 | Mar 31, 2024 | -$27.90M | – |
| Q4 FY2023CQ4 2023 | Dec 31, 2023 | -$31.40M | – |
| Q3 FY2023CQ3 2023 | Sep 30, 2023 | -$60.10M | – |
| Q2 FY2023CQ2 2023 | Jun 30, 2023 | -$113.70M | – |
| Q1 FY2023CQ1 2023 | Mar 31, 2023 | -$52.20M | – |
| Q4 FY2022CQ4 2022 | Dec 31, 2022 | -$52.20M | – |
| Q3 FY2022CQ3 2022 | Sep 30, 2022 | -$45.00M | – |
| Q2 FY2022CQ2 2022 | Jun 30, 2022 | -$17.80M | – |
| Q1 FY2022CQ1 2022 | Mar 31, 2022 | -$25.60M | – |
| Q4 FY2020CQ2 2020 | Jun 30, 2020 | -$68.30M | – |
| Q3 FY2020CQ1 2020 | Mar 31, 2020 | -$133.70M | -2366.1% |
| Q2 FY2020CQ4 2019 | Dec 31, 2019 | -$8.80M | -244.3% |
| Q1 FY2020CQ3 2019 | Sep 30, 2019 | -$20.90M | -1841.7% |
| Q4 FY2019CQ2 2019 | Jun 30, 2019 | -$5.60M | -131.5% |
| Q3 FY2019CQ1 2019 | Mar 31, 2019 | $5.90M | -57.2% |
| Q2 FY2019CQ4 2018 | Dec 31, 2018 | $6.10M | -3.2% |
| Q1 FY2019CQ3 2018 | Sep 30, 2018 | $1.20M | -98.6% |
| Q4 FY2018CQ2 2018 | Jun 30, 2018 | $17.80M | -5.8% |
| Q3 FY2018CQ1 2018 | Mar 31, 2018 | $13.80M | +150.9% |
| Q2 FY2018CQ4 2017 | Dec 31, 2017 | $6.30M | -63.4% |
| Q1 FY2018CQ3 2017 | Sep 30, 2017 | $84.00M | +1083.1% |
| Q4 FY2017CQ2 2017 | Jun 30, 2017 | $18.90M | -14.9% |
| Q3 FY2017CQ1 2017 | Mar 31, 2017 | $5.50M | -87.1% |
| Q2 FY2017CQ4 2016 | Dec 31, 2016 | $17.20M | -61.9% |
| Q1 FY2017CQ3 2016 | Sep 30, 2016 | $7.10M | -83.6% |
| Q4 FY2016CQ2 2016 | Jun 30, 2016 | $22.20M | -37.6% |
| Q3 FY2016CQ1 2016 | Mar 31, 2016 | $42.60M | +19.3% |
| Q2 FY2016CQ4 2015 | Dec 31, 2015 | $45.20M | – |
| Q1 FY2016CQ3 2015 | Sep 30, 2015 | $43.30M | – |
| Q4 FY2015CQ2 2015 | Jun 30, 2015 | $35.60M | – |
| Q3 FY2015CQ1 2015 | Mar 31, 2015 | $35.70M | – |
See a number that looks wrong?